Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice
Infection and Immunity · 2023
DOI: 10.1128/iai.00097-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, 2023. Verfasst von Rachele Gore und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurodevelopment in Health and Disease Research Program, School of Health and Biomedical Sciences, RMIT University , Bundoora, Victoria, Australia. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Enterotoxigenic Escherichia coli, Escherichia coli Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Immuron.
Abstract (Originalsprache)
Enterotoxigenic Escherichia coli (ETEC) is a leading cause of bacterial diarrhea with the potential to cause long-term gastrointestinal (GI) dysfunction. Preventative treatments for ETEC-induced diarrhea exist, yet the effects of these treatments on GI commensals in healthy individuals are unclear. Whether administration of a prophylactic preventative treatment for ETEC-induced diarrhea causes specific shifts in gut microbial populations in controlled environments is also unknown. Here, we studied the effects of a hyperimmune bovine colostrum (IMM-124E) used in the manufacture of Travelan (AUST L 106709) on GI bacteria in healthy C57BL/6 mice. Using next-generation sequencing, we aimed to test the onset and magnitude of potential changes to the mouse gut microbiome in response to the antidiarrheagenic hyperimmune bovine colostrum product, rich in immunoglobulins against select ETEC strains (Travelan, Immuron Ltd). We show that in mice administered colostrum containing lipopolysaccharide (LPS) antibodies, there was an increased abundance of potentially gut-beneficial bacteria, such as Akkermansia and Desulfovibrio, without disrupting the underlying ecology of the GI tract. Compared to controls, there was no difference in overall weight gain, body or cecal weights, or small intestine length following LPS antibody colostrum supplementation. Overall, dietary supplementation with colostrum containing LPS antibodies produced subtle alterations in the gut bacterial composition of mice. Primarily, Travelan LPS antibody treatment decreased the ratio of Firmicutes/Bacteroidetes in gut microbial populations in unchallenged healthy mice. Further studies are required to examine the effect of Travelan LPS antibody treatment to engineer the microbiome in a diseased state and during recovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurodevelopment in Health and Disease Research Program, School of Health and Biomedical Sciences, RMIT University , Bundoora, Victoria, Australia.
- Department of Microbiology, Anatomy, Physiology and Pharmacology, La Trobe University , Bundoora, Victoria, Australia.
- Department of Physiology and Cell Biology, Kobe University School of Medicine , Kobe, Japan.
ORCID-Profile: Jennifer L Wood, Ashley E Franks
Förderung
- Immuron
Zitieren
APA
Gore, R., Mohsenipour, M., Wood, J. L., Balasuriya, G. K., Hill-Yardin, E. L., & Franks, A. E. (2023). Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice. Infection and Immunity. https://doi.org/10.1128/iai.00097-23
Vancouver
Gore R, Mohsenipour M, Wood JL, Balasuriya GK, Hill-Yardin EL, Franks AE. Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice. Infection and Immunity. 2023. doi:10.1128/iai.00097-23
BibTeX
@article{Gore2023,
author = {Gore, Rachele and Mohsenipour, Mitra and Wood, Jennifer L and Balasuriya, Gayathri K and Hill-Yardin, Elisa L and Franks, Ashley E},
title = {Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice},
journal = {Infection and Immunity},
year = {2023},
doi = {10.1128/iai.00097-23}
}
EUVIMED